Moleculin Biotech (NASDAQ:MBRX) Announces Quarterly Earnings Results, Misses Expectations By $0.72 EPS

Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings results on Friday. The company reported ($9.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($8.87) by ($0.72), FiscalAI reports.

Moleculin Biotech Stock Performance

MBRX traded down $0.19 during midday trading on Friday, reaching $7.87. 9,899 shares of the company were exchanged, compared to its average volume of 46,415. The company has a market cap of $8.11 million, a price-to-earnings ratio of -0.06 and a beta of 2.11. Moleculin Biotech has a one year low of $3.23 and a one year high of $229.40. The company’s fifty day moving average price is $9.94 and its 200 day moving average price is $36.71.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Wall Street Zen downgraded shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Finally, HC Wainwright reduced their price objective on shares of Moleculin Biotech to $60.00 and set a “buy” rating for the company in a report on Friday, August 28th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $60.00.

About Moleculin Biotech

Moleculin Biotech is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing treatments for cancer and other serious diseases. Its research centers on drug candidates intended to address cancers that can be difficult to treat with existing therapies. The company’s pipeline includes Annamycin, an investigational anthracycline being studied for acute myeloid leukemia and soft-tissue sarcoma that has spread to the lungs. Moleculin has described Annamycin as designed to avoid some limitations associated with older anthracyclines, including heart-related toxicity.